A Phase 3 interventional study of 18F-fluciclovine PET CT in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 17 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-28.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing fluciclovine F-18 in Prostatic Neoplasms — 2 open to participants now, 3 under way, none of them phase 3. fluciclovine F-18 · Prostatic Neoplasms.
Among the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, this one has the largest enrollment, is the only one that started in 2016, is the only one in phase 3, and was the 6th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Blue Earth Diagnostics · Sites in United States
Ages 18+ · Men only
Brigham and Women's Hospital · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
fluciclovine F-18: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 2 · Phase 4 3
First in 2007; this study’s year is marked. 1 started in 2016.
This study's enrollment of 221 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 28 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
13 studies in Prostatic Neoplasms by Bracco: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Prostatic Neoplasms by Bracco, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 3, and was the 6th registered.
Bracco’s Prostatic Neoplasms studies by the year they started, since 2009.
2 of the studies testing fluciclovine F-18 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05722925OHSU Knight Cancer InstituteEvaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | 2026-12-01 |
| NCT06062745Brigham and Women's HospitalPilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, from their registry updates:
Among Bracco’s 13 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging. Consenting participants will be imaged with 18F-fluciclovine PET/CT. Site clinicians will manage study subjects per standard practices and will document any change in treatment based on review of 18F-fluciclovine PET/CT findings. All participants will be followed for up to 6 months, with clinical data collected for this study. An interdisciplinary panel will provide expert guidance to local readers on request. The final reporting of the PET/CT scan will be a single report by the local reader following any such discussion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous administration of 18F-fluciclovine PET CT.
Drug: 18F-fluciclovine PET CT
Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
Also known as: FACBC
The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.
The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT
Time frame: 2-22 days post PET CT
The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Actual Treatment
The change of management will be based on referring physician questionnaires completed pre- 18F-fluciclovine PET/CT and changes reported at 6 month follow-up. Investigators were instructed to assess any clinically significant change from the revised management plan.
Time frame: 6 months
The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population
The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT
Time frame: 1 week
The Rate of Detection of Disease in 1) Prostate and Prostate Bed and 2) Extra-prostatic Regions With 18F-fluciclovine PET/CT in the Study Population
The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally
Time frame: 1 week
The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy
Based on the ratio of positive findings in the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI
Time frame: 6 months
The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy
Based on the ratio of positive findings outside the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI
Time frame: 6 months
The study was conducted between 01 June 2016 (first patient, screening visit) and 01 November 2017 (last patient, last contact) at 17 sites in the USA. Overall 17 sites were initiated, of which 15 sites enrolled patients.
| Milestone | 18F-fluciclovine PET CT |
|---|---|
| Started | 221 |
| Received 18f-fluciclovine | 213 |
| Completed | 211 |
| Not completed | 10 |
| Withdrew: Withdrawal prior to 18f-fluciclovine pet | 8 |
| Withdrew: Lost to follow-up | 2 |
The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT
| Participants | 18F-fluciclovine PET CT |
|---|---|
| Overall Evaluable Analysis Set — Patients with Revised Management Plan | 126 |
| Overall Evaluable Analysis Set — No Revision to Management Plan | 87 |
| Positive 18F-fluciclovine Scan — Patients with Revised Management Plan | 88 |
| Positive 18F-fluciclovine Scan — No Revision to Management Plan | 34 |
| Negative 18F-fluciclovine Scan — Patients with Revised Management Plan | 38 |
| Negative 18F-fluciclovine Scan — No Revision to Management Plan | 53 |
The change of management will be based on referring physician questionnaires completed pre- 18F-fluciclovine PET/CT and changes reported at 6 month follow-up. Investigators were instructed to assess any clinically significant change from the revised management plan.
| Participants | 18F-fluciclovine PET CT |
|---|---|
| Overall — Change from the revised management plan | 80 |
| Overall — No change from the revised management plan | 131 |
| Positive 18F fluciclovine Scan — Change from the revised management plan | 47 |
| Positive 18F fluciclovine Scan — No change from the revised management plan | 74 |
| Negative 18F fluciclovine Scan — Change from the revised management plan | 33 |
| Negative 18F fluciclovine Scan — No change from the revised management plan | 57 |
The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT
| Participants | 18F-fluciclovine PET CT |
|---|---|
| The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population | 122 |
The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally
| Participants | 18F-fluciclovine PET CT |
|---|---|
| Prostate or Prostate Bed | 64 |
| Extra-prostatic | 80 |
Based on the ratio of positive findings in the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI
| Percentage of scans | 18F-fluciclovine PET CT |
|---|---|
| The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy | 100 (92.1 to 100.0) |
Based on the ratio of positive findings outside the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI
| Percentage of scans | 18F-fluciclovine PET CT |
|---|---|
| The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy | 100 (90.5 to 100.0) |
Collected over As specified in the Statistical Analysis Plan, results are presented as only those treatment-emergent adverse events which occurred up to 42 days after the 18F fluciclovine administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 18F-fluciclovine PET CT | 0/213 (0%) | 0/213 (0%) | 44/213 (20.7%) |
| Event | 18F-fluciclovine PET CT |
|---|---|
| DiarrhoeaGastrointestinal disorders | 6/213 |
| HeadacheNervous system disorders | 6/213 |
| ConstipationGastrointestinal disorders | 2/213 |
| HaematuriaRenal and urinary disorders | 2/213 |
| NocturiaRenal and urinary disorders | 2/213 |
| PollakiuriaRenal and urinary disorders | 2/213 |
| Urinary IncontinenceRenal and urinary disorders | 2/213 |
| Oedema peripheralGeneral disorders | 2/213 |
| AnxietyPsychiatric disorders | 2/213 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/213 |
Full Analysis Set
| Age, Continuous(years) | 18F-fluciclovine PET CT |
|---|---|
| Median | 67.0 (46 to 90) |
| Sex: Female, Male(Participants) | 18F-fluciclovine PET CT |
|---|---|
| Female | 0 |
| Male | 213 |
| Ethnicity (NIH/OMB)(Participants) | 18F-fluciclovine PET CT |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 202 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | 18F-fluciclovine PET CT |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 17 |
| White | 188 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | 18F-fluciclovine PET CT |
|---|---|
| United States | 213 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2016 to primary completion in Nov 2017, 17 months.
Results were first posted in Jan 2019, 1 year 2 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 17 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluciclovine F-18